Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit.
Diaphragm
/ drug effects
Dose-Response Relationship, Drug
Fentanyl
/ pharmacology
Heroin
/ toxicity
Humans
Laryngismus
/ chemically induced
Muscle Rigidity
/ chemically induced
Naloxone
/ pharmacology
Narcotic Antagonists
/ pharmacology
Opiate Overdose
/ drug therapy
Receptors, Opioid, mu
/ drug effects
Thoracic Wall
/ drug effects
fentany
fentanyl analogue
naloxone
opioid overdose
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
19
05
2021
accepted:
22
05
2021
pubmed:
11
6
2021
medline:
5
2
2022
entrez:
10
6
2021
Statut:
ppublish
Résumé
Food and Drug Administration (FDA) risk evaluation and mitigation strategies (REMs) encourage emergency responders, paramedics, law enforcement agents, and even laypeople to be trained in the administration of naloxone with the intent of rescuing individuals from a known or suspected opioid overdose. Although naloxone is generally safe and effective at reversing respiratory depression caused by a conventional opioid such as morphine or heroin by competing with the opioid and displacing it from the μ-opioid receptor, questions increasingly are arising as to whether naloxone can adequately reverse opioid overdoses that may involve the potent opioids fentanyl and its analogues (F/FAs). In other words, as more and more opioid overdoses involve F/FAs, can naloxone keep up? As a competitive antagonist at μ-opioid receptors, naloxone is often a life-saving agent in cases of overdose caused by conventional opioids, but it may not be versatile or powerful enough to combat the rising tide of overdoses due to fentanyl and its illicit analogues, or in cases of overdose involving combinations of opioids and non-opioids.
Substances chimiques
Narcotic Antagonists
0
Receptors, Opioid, mu
0
Naloxone
36B82AMQ7N
Heroin
70D95007SX
Fentanyl
UF599785JZ
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1501-1504Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Torralva R, Janowsky A. Noradrenergic mechanisms in fentanyl-mediated rapid death explain failure of naloxone in the opioid crisis. J Pharmacol Exp Ther. 2019;371:453-475.
Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology. 2018;134:121-132.
Frank RG, Pollack HA. Addressing the fentanyl threat to public health. N Engl J Med. 2017;376:605-607.
DEA. (2018) Fentanyl. In: Fentanyl, Vol. 2019. Washington, DC: Drug Enforcement Agency.
Misailidi N, Papoutsis I, Nikolaou P, Dona A, Spiliopoulou C, Athanaselis S. Fentanyls continue to replace heroin in the drug arena: the cases of ocfentanil and carfentanil. Forensic Toxicol. 2018;36:12-32.
Lötsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G. Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet. 2013;52:23-36.
Gill H, Kelly E, Henderson G. How the complex pharmacology of the fentanyls contributes to their lethality. Addiction. 2019;114:1524-1525.
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9:63-88.
Schmid CL, Kennedy NM, Ross NC, et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. 2017;171:1165-1175.e1113.
Phalen P, Ray B, Watson DP, Huynh P, Greene MS. Fentanyl related overdose in Indianapolis: Estimating trends using multilevel Bayesian models. Addict Behav. 2018;86:4-10.
Spencer MR, Warner M, Bastian BA, Trinidad JP, Hedegaard H. Drug overdose deaths involving fentanyl, 2011-2016. Natl Vital Stat Rep. 2019;68:1-19.
Baumann MH, Kopajtic TA, Madras BK. Pharmacological research as a key component in mitigating the opioid overdose crisis. Trends Pharmacol Sci. 2018;39:995-998.
Somerville NJ, O’Donnell J, Gladden RM, et al. Characteristics of fentanyl overdose - Massachusetts, 2014-2016. MMWR Morb Mortal Wkly Rep. 2017;66:382-386.
Kuczyńska K, Grzonkowski P, Kacprzak Ł, Zawilska JB. Abuse of fentanyl: An emerging problem to face. Forensic Sci Int. 2018;289:207-214.
Moss RB, Pryor MM, Baillie R, et al. Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level. PLoS One. 2020;15:e0234683.
Haouzi P, Guck D, McCann M, Sternick M, Sonobe T, Tubbs N. Severe hypoxemia prevents spontaneous and naloxone-induced breathing recovery after fentanyl overdose in awake and sedated rats. Anesthesiology. 2020;132:1138-1150.
Scamman FL. Fentanyl-O2-N2O rigidity and pulmonary compliance. Anesth Analg. 1983;62:332-334.
Lui PW, Lee TY, Chan SH. Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat. Neurosci Lett. 1989;96:114-119.
Fu MJ, Tsen LY, Lee TY, Lui PW, Chan SH. Involvement of cerulospinal glutamatergic neurotransmission in fentanyl-induced muscular rigidity in the rat. Anesthesiology. 1997;87:1450-1459.
Streisand J, Bailey P, LeMaire L, et al. Fentanyl-induced rigidity and unconsciousness in human volunteers. Incidence, duration, and plasma concentrations. Anesthesiology. 1993;78:629-634.
Burns G, DeRienz RT, Baker DD, Casavant M, Spiller HA. Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse? Clin Toxicol (Phila). 2016;54:420-423.
Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367:146-155.
Slavova S, Costich JF, Bunn TL, et al. Heroin and fentanyl overdoses in Kentucky: Epidemiology and surveillance. Int J Drug Policy. 2017;46:120-129.
Evans JM, Hogg MI, Lunn JN, Rosen M. Degree and duration of reversal by naloxone of effects of morphine in conscious subjects. Br Med J. 1974;2:589-591.
Weber JM, Tataris KL, Hoffman JD, Aks SE, Mycyk MB. Can nebulized naloxone be used safely and effectively by emergency medical services for suspected opioid overdose? Prehosp Emerg Care. 2012;16:289-292.
Barton ED, Colwell CB, Wolfe T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005;29:265-271.
Robertson TM, Hendey GW, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emerg Care. 2009;13:512-515.
Moss RB, Carlo DJ. Higher doses of naloxone are needed in the synthetic opioid era. Subst Abuse Treat Prev Policy. 2019;14:6.
Wermeling DP. Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf. 2015;6:20-31.
Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172-179.
Kim HK, Connors NJ, Mazer-Amirshahi ME. The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs. Expert Opin Drug Saf. 2019;18:465-475.
Faul M, Lurie P, Kinsman JM, Dailey MW, Crabaugh C, Sasser SM. Multiple naloxone administrations among emergency medical service providers is increasing. Prehosp Emerg Care. 2017;21:411-419.
Belz D, Lieb J, Rea T, Eisenberg MS. Naloxone use in a tiered-response emergency medical services system. Prehosp Emerg Care. 2006;10:468-471.